Compugen Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| MAIA-Ovarian Trial Interim Analysis | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2K
Cash and Cash Equivalents Balance Quarterly134.9MTarget: Maintain sufficient capital for clinical trials
MAIA-Ovarian Trial Patient Enrollment QuarterlyTarget: Complete enrollment for randomized trial
Watch Items
- MAIA-Ovarian Trial Preliminary Interim AnalysisTrigger: First Quarter of 2027 (Q1 2027)Action: Evaluate efficacy and safety data to determine adaptive expansion or combination trials.
- AstraZeneca Rilvegostomig Phase 3 Trial ProgressTrigger: Ongoing Phase 3 trials in lung, gastrointestinal, and endometrial cancersAction: Monitor clinical milestones that trigger future milestone payments and royalty streams.
- Gilead-partnered GS-0321 Phase 1 Trial ProgressTrigger: Completion of Phase 1 dose escalationAction: Prepare for transition of clinical development leadership to Gilead for Phase 2.
Research as of 20 Jun 2026